This company listing is no longer active
Resumen de acción 8IY
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 1 riesgos adicionales
Competidores de Yumanity Therapeutics, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.47 |
| 52 Week High | US$3.10 |
| 52 Week Low | US$0.88 |
| Beta | 0 |
| 1 Month Change | -13.53% |
| 3 Month Change | -10.91% |
| 1 Year Change | -47.87% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -92.02% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 8IY | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | -21.8% | 2.1% | -1.0% |
| 1Y | -47.9% | -22.4% | 2.0% |
Rentabilidad vs. Industria: 8IY underperformed the German Biotechs industry which returned 4.7% over the past year.
Rentabilidad vs. Mercado: 8IY underperformed the German Market which returned -19.2% over the past year.
Volatilidad de los precios
| 8IY volatility | |
|---|---|
| 8IY Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: 8IY's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: 8IY's weekly volatility has decreased from 15% to 9% over the past year, but is still higher than 75% of German stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2014 | 41 | Richard Peters | www.yumanity.com |
Resumen de fundamentos de Yumanity Therapeutics, Inc.
| Estadísticas fundamentales de 8IY | |
|---|---|
| Capitalización bursátil | €135.42m |
| Beneficios(TTM) | -€30.17m |
| Ingresos (TTM) | €4.57m |
29.7x
Ratio precio-ventas (PS)-4.5x
Ratio precio-beneficio (PE)¿Está 8IY sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 8IY | |
|---|---|
| Ingresos | US$4.84m |
| Coste de los ingresos | US$12.45m |
| Beneficio bruto | -US$7.60m |
| Otros gastos | US$24.40m |
| Beneficios | -US$32.00m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.95 |
| Margen bruto | -156.97% |
| Margen de beneficio neto | -660.75% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado 8IY a largo plazo?
Ver rendimiento histórico y comparativa